Roche Pharmaceutical Development and Sales Overview
Changes to the development pipeline
Q3 2022 update
2 NMES:
New to phase I
RG6536 vixarelimab - immunology
RG6538 P-BCMA-ALLO1 - multiple myeloma
New to phase II
New to phase III
1 NME:
4 Als:
RG7314 balovaptan - post-traumatic stress
disorder
RG6168 Enspryng - MOG-AD
T
RG6168 Enspryng - autoimmune encephalitis
I
Removed from phase II
Removed from phase I
2 NMES:
Status as of October 18, 2022
RG7907 CPAM (2) - HBV
RG6147 galegenimab (HtrA1) - geographic
atrophy
1 Al (removed by Chugai):
CHU Oncolytic Type 5 adenovirus -
esophageal cancer
I RG6058 tiragolumab - 1L non-squamous
NSCLC (SKYSCRAPER-06)
RG3625 TNKase - stroke (FPI 2019)
Roche
New to registration
1 NME (First filed in China*):
RG6017 crovalimab - PNH
Removed from phase III
1 NME (EU):
1 Al:
RG7446 Tecentriq - RCC adj
Approvals
RG7716 Vabysmo - DME
1 AI (EU):
RG7716 Vabysmo - WAMD
1 AI (US):
RG6512 Xofluza - influenza pediatric
*US/EU filing expected 2023
52
52View entire presentation